Association Between Postnatal Steroid Use and Long-term Neurodevelopmental Impairment : A Systematic Review

Association Between Postnatal Steroid Use and Long-term Neurodevelopmental Impairment : A Systematic Review

Authors

  • Deskafiani Putri General Practitioner, Annisa Mother and Child Hospital, Pekanbaru, Indonesia
  • Firman Syahbana Pediatrician, Annisa Mother and Child Hospital, Pekanbaru, Indonesia

Keywords:

Postnatal corticosteroids, dexamethasone, hydrocortisone, preterm infants, neurodevelopmental impairment, cerebral palsy, bronchopulmonary dysplasia

Abstract

Introduction: Postnatal systemic corticosteroids are used to prevent or treat bronchopulmonary dysplasia (BPD) in preterm infants, but concerns persist regarding their association with long-term neurodevelopmental impairment (NDI). This systematic review synthesizes evidence on the association between postnatal steroid use (dexamethasone and hydrocortisone) and long-term neurodevelopmental outcomes.

Methods: A systematic review was conducted following PRISMA guidelines. We screened studies based on predefined criteria: neonatal exposure to systemic postnatal corticosteroids, comparison groups, neurodevelopmental outcomes assessed at ≥12 months corrected age, and RCT or high-quality observational design. Data extraction covered study design, population, steroid regimen, neurodevelopmental outcomes, follow-up timing, association results, and confounding factors. A total of 80 studies were included.

Results: Early dexamethasone (<7-8 days) consistently increased cerebral palsy (CP) risk (RR 1.77, 95% CI 1.21-2.58; Doyle et al., 2021). Late dexamethasone (≥7 days) showed no significant CP increase. Early hydrocortisone did not significantly increase CP (RR 1.06, 95% CI 0.67-1.67; Morris et al., 2019) and improved survival without moderate-severe NDI in some analyses. Late hydrocortisone showed neutral neurodevelopmental effects in large RCTs at 2 years and school age. Dose-response relationships were observed for both agents. Gestational age and baseline BPD risk modified treatment effects.

Discussion: Apparent contradictions in the literature are reconciled by considering timing of initiation (early vs late), steroid type (dexamethasone vs hydrocortisone), cumulative dose, historical regimens versus current low-dose protocols, confounding by indication, competing mortality risk, and effect modification by gestational age and BPD risk. Early dexamethasone is consistently harmful, while hydrocortisone appears predominantly neutral but with dose-dependent signals.

Conclusion: Early dexamethasone should be avoided. Late dexamethasone and hydrocortisone have more favorable profiles but require careful patient selection. The benefit-risk balance is most favorable for extremely preterm infants at highest BPD risk. Further school-age follow-up studies are needed.

References

Doyle L, Cheong J, Hay S, et al (2021) Early (< 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD001146.pub6

Uberos J, Vélez-Moreno E, Díaz-Granados I, et al (2025) Perinatal Treatment with Corticosteroids and Its Relation with Neurodevelopment in Premature Newborns: A Systematic Review of the Literature. Turkish archives of pediatrics. https://doi.org/10.5152/TurkArchPediatr.2025.24299

AlsuhaymiZuhairHamdan A, Al-Wahbi ZM, Alanazi A, et al (2017) Postnatal Corticosteroids to Treat or Prevent Bronchopulmonary Dysplasia in Preterm Infants. The Egyptian Journal of Hospital Medicine. https://doi.org/10.12816/0042866

Hay S, Ovelman C, Zupancic J, et al (2020) Systemic corticosteroids for the prevention of bronchopulmonary dysplasia, a network meta-analysis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD013730

Wolbeek MT, Sonneville L, Vries WB, et al (2013) Early life intervention with glucocorticoids has negative effects on motor development and neuropsychological function in 14–17year-old adolescents. Psychoneuroendocrinology. https://doi.org/10.1016/j.psyneuen.2012.10.001

Jenkinson AC, Kaltsogianni O, Dassios T, Greenough A (2023) Systematic review of the long-term effects of postnatal corticosteroids. Journal of Perinatal Medicine. https://doi.org/10.1515/jpm-2023-0297

Doyle L, Cheong J, Hay S, et al (2021) Late (≥ 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD001145.pub5

Doyle L, Ehrenkranz R, Halliday H (2010) Dexamethasone Treatment after the First Week of Life for Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review. Neonatology. https://doi.org/10.1159/000286212

Doyle L, Halliday H, Ehrenkranz R, et al (2014) An update on the impact of postnatal systemic corticosteroids on mortality and cerebral palsy in preterm infants: effect modification by risk of bronchopulmonary dysplasia. Jornal de Pediatria. https://doi.org/10.1016/j.jpeds.2014.07.049

Buchiboyina A, Yip CSA, Kohan R, et al (2020) Effect of cumulative dexamethasone dose in preterm infants on neurodevelopmental and growth outcomes: a Western Australia experience. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2020-319147

Watterberg K, Walsh MC, Li L, et al (2022) Hydrocortisone to Improve Survival Without Bronchopulmonary Dysplasia. Obstetric Anesthesia Digest. https://doi.org/10.1097/01.aoa.0000853600.69809.12

Baat T de, Loo M van de, Aarnoudse-Moens C, et al (2025) Effect of Systemic Hydrocortisone in Ventilated Infants Born Preterm: Mortality and 5.5 Year Neurodevelopmental Outcomes of a Randomized Clinical Trial. Jornal de Pediatria. https://doi.org/10.1016/j.jpeds.2025.114954

Morris I, Goel N, Chakraborty M (2019) Efficacy and safety of systemic hydrocortisone for the prevention of bronchopulmonary dysplasia in preterm infants: a systematic review and meta-analysis. European Journal of Pediatrics. https://doi.org/10.1007/s00431-019-03398-5

Demauro S, Kirpalani H, Hintz S, et al (2025) Hydrocortisone in Preterm Infants and School-Age Functional Outcomes: Follow-Up of a Randomized Clinical Trial. JAMA pediatrics. https://doi.org/10.1001/jamapediatrics.2025.4801

Baud O, Trousson C, Biran V, et al (2018) Two-year neurodevelopmental outcomes of extremely preterm infants treated with early hydrocortisone: treatment effect according to gestational age at birth. Archives of Disease in Childhood: Fetal and Neonatal Edition. https://doi.org/10.1136/archdischild-2017-313756

Halbmeijer N, Sonnaert M, Swarte RMC, et al (2023) Identifying effect modifiers of systemic hydrocortisone treatment initiated 7–14 days after birth in ventilated very preterm infants on long-term outcome: secondary analysis of a randomised controlled trial. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2023-325558

Kim MS, Oh M, Tomita E, et al (2025) Cumulative Hydrocortisone Exposure and Early Brain Volumetrics in Very Low Birth Weight Infants: Associations with Neurodevelopmental Outcomes. Biomedicines. https://doi.org/10.3390/biomedicines13112765

Patra K, Greene MM, Silvestri JM (2014) Neurodevelopmental impact of hydrocortisone exposure in extremely low birth weight infants: outcomes at 1 and 2 years. Journal of Perinatology. https://doi.org/10.1038/jp.2014.133

许巍 (2016) Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Yearbook of Neonatal and Perinatal Medicine. https://doi.org/10.3760/CMA.J.ISSN.1673-4408.2016.02.104

Yates H, Newell S (2011) Postnatal intravenous steroids and long-term neurological outcome: recommendations from meta-analyses. Archives of Disease in Childhood: Fetal and Neonatal Edition. https://doi.org/10.1136/adc.2010.208868

David J, Foschi CM, Greene MM, et al (2025) Neurodevelopmental Outcome at 20 Months Corrected Age in Extremely Preterm Infants After Exposure to Dexamethasone and Hydrocortisone in the NICU. The Journal of Pediatric Pharmacology and Therapeutics. https://doi.org/10.5863/1551-6776-30.1.84

Boscarino G, Cardilli V, Conti M, et al (2024) Outcomes of postnatal systemic corticosteroids administration in ventilated preterm newborns: a systematic review of randomized controlled trials. Frontiers in Pediatrics. https://doi.org/10.3389/fped.2024.1344337

Onland W, Jaegere ADD, Offringa M, Kaam AV van (2017) Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD010941.pub2

Baud O, Trousson C, Biran V, et al (2017) Association Between Early Low-Dose Hydrocortisone Therapy in Extremely Preterm Neonates and Neurodevelopmental Outcomes at 2 Years of Age. Journal of the American Medical Association (JAMA). https://doi.org/10.1001/jama.2017.2692

Doyle L, Cheong J, Ehrenkranz R, Halliday H (2017) Late (> 7 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD001145.pub4

Doyle L, Ehrenkranz R, Halliday H (2014) Early (< 8 days) postnatal corticosteroids for preventing chronic lung disease in preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD001146.pub4

Doyle L, Ehrenkranz R, Halliday H (2010) Postnatal Hydrocortisone for Preventing or Treating Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review. Neonatology. https://doi.org/10.1159/000279992

Purdy I, Smith L, Wiley D, Badr L (2013) A Psychoneuroimmunologic Examination of Cumulative Perinatal Steroid Exposures and Preterm Infant Behavioral Follow-Up. Biological Research for Nursing. https://doi.org/10.1177/1099800411420134

Doyle L, Ehrenkranz R, Halliday H (2010) Dexamethasone Treatment in the First Week of Life for Preventing Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review. Neonatology. https://doi.org/10.1159/000286210

LeFlore1 J, Engle2 W (2011) Growth and Neurodevelopment in Extremely Low-Birth-Weight Neonates Exposed to Postnatal Steroid Therapy. American Journal of Perinatology. https://doi.org/10.1055/s-0031-1276738

Halbmeijer N, Onland W, Cools F, et al (2021) Effect of Systemic Hydrocortisone Initiated 7 to 14 Days After Birth in Ventilated Preterm Infants on Mortality and Neurodevelopment at 2 Years' Corrected Age: Follow-up of a Randomized Clinical Trial. Journal of the American Medical Association (JAMA). https://doi.org/10.1001/jama.2021.9380

Lardón M, Uberos J, Narbona E (2016) [Does corticosteroid treatment during the pre and postnatal periods affect the neurodevelopmental outcome of premature newborns?]. Biomedica : revista del Instituto Nacional de Salud. https://doi.org/10.7705/biomedica.v37i3.3394

Raghuveer T, Zackula R, Lakhotia R, Binder SA (2024) Systemic steroids and bronchopulmonary dysplasia: a systematic review and meta-analysis. Journal of Perinatology. https://doi.org/10.1038/s41372-024-02097-w

Peltoniemi O, Lano A, Yliherva A, et al (2016) Randomised trial of early neonatal hydrocortisone demonstrates potential undesired effects on neurodevelopment at preschool age. Acta paediatrica. https://doi.org/10.1111/apa.13074

Rocha G, Calejo R, Arnet V, et al (2024) The use of two or more courses of low-dose systemic dexamethasone to extubate ventilator-dependent preterm neonates may be associated with a higher prevalence of cerebral palsy at two years of corrected age. Early Human Development. https://doi.org/10.1016/j.earlhumdev.2024.106050

(2021) Dexamethasone dose and risk of preterm neurodevelopmental impairment. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.15478

Onland W, Loo M van de, Offringa M, Kaam AV van (2023) Systemic corticosteroid regimens for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd010941

Keunen K, Kersbergen K, Groenendaal F, et al (2012) Brain tissue volumes in preterm infants: prematurity, perinatal risk factors and neurodevelopmental outcome: A systematic review. Journal of Maternal-Fetal & Neonatal Medicine. https://doi.org/10.3109/14767058.2012.664343

Ofman G, Perez M, Farrow K (2018) Early low-dose hydrocortisone: is the neurodevelopment affected? Journal of Perinatology. https://doi.org/10.1038/s41372-018-0086-y

Shah SS, Ohlsson A, Halliday H, Shah V (2017) Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD002058.pub3

Parikh N, Kennedy K, Lasky R, Tyson J (2015) Neurodevelopmental Outcomes of Extremely Preterm Infants Randomized to Stress Dose Hydrocortisone. PLoS ONE. https://doi.org/10.1371/journal.pone.0137051

Watterberg KL, Walsh M, Li L, et al (2022) Hydrocortisone to Improve Survival without Bronchopulmonary Dysplasia. New England Journal of Medicine. https://doi.org/10.1056/NEJMoa2114897

Harrold J, Ali S, Oleszczuk M, et al (2013) Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: an overview of Cochrane reviews. Evidence-based Child Health: A Cochrane Review Journal. https://doi.org/10.1002/EBCH.1955

Zeng L, Tian J, Song F, et al (2018) Corticosteroids for the prevention of bronchopulmonary dysplasia in preterm infants: a network meta-analysis. Archives of Disease in Childhood: Fetal and Neonatal Edition. https://doi.org/10.1136/archdischild-2017-313759

Loo M van de, Kaam AV van, Offringa M, et al (2024) Corticosteroids for the prevention and treatment of bronchopulmonary dysplasia: an overview of systematic reviews. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD013271.pub2

Aho L, Immeli L, Lano A, Metsäranta M (2025) Cognitive Outcomes of Extremely Preterm Infants at 6.5 Years after Postnatal Corticosteroid Treatment: A Pilot Study. Neonatology. https://doi.org/10.1159/000548091

Shaffer M, Baud O, Lacaze‐Masmonteil T, et al (2019) Effect of Prophylaxis for Early Adrenal Insufficiency Using Low-Dose Hydrocortisone in Very Preterm Infants: An Individual Patient Data Meta-Analysis. Jornal de Pediatria. https://doi.org/10.1016/j.jpeds.2018.10.004

Shah SS, Ohlsson A, Halliday H, Shah V (2017) Inhaled versus systemic corticosteroids for the treatment of bronchopulmonary dysplasia in ventilated very low birth weight preterm infants. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD002057.pub4

Drozdowicz L, Bostwick J (2014) Psychiatric adverse effects of pediatric corticosteroid use. Mayo Clinic proceedings. https://doi.org/10.1016/j.mayocp.2014.01.010

Szabó H, Baraldi E, Colin A (2021) Corticosteroids in the prevention and treatment of infants with bronchopulmonary dysplasia: Part I. systemic corticosteroids. Pediatric Pulmonology. https://doi.org/10.1002/ppul.25805

Ogunlesi T, Odigwe C, Oladapo O (2015) Adjuvant corticosteroids for reducing death in neonatal bacterial meningitis. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.CD010435.pub2

Aucott SW, Watterberg K, Shaffer ML, et al (2010) Early cortisol values and long-term outcomes in extremely low birth weight infants. Journal of Perinatology. https://doi.org/10.1038/jp.2009.191

Zyblewski S, Martin RH, Shipes VB, et al (2021) Intraoperative methylprednisolone and neurodevelopmental outcomes in infants after cardiac surgery. Annals of Thoracic Surgery. https://doi.org/10.1016/j.athoracsur.2021.04.006

Kovacs K, Szakmar E, Dobi M, et al (2025) Neurodevelopmental outcome in infants with neonatal encephalopathy receiving hydrocortisone during therapeutic hypothermia: follow-up of the extended-CORTISoL trial. Journal of Perinatology. https://doi.org/10.1038/s41372-025-02428-5

Marr BL, Mettelman BB, Bode MM, Gross S (2019) Randomized Trial of 42-Day Compared with 9-Day Courses of Dexamethasone for the Treatment of Evolving Bronchopulmonary Dysplasia in Extremely Preterm Infants. Jornal de Pediatria. https://doi.org/10.1016/j.jpeds.2019.04.047

(2022) Late hydrocortisone does not prevent bronchopulmonary dysplasia. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.16027

Onland W, Kaam AV van, Jaegere ADD, Offringa M (2010) Open-Label Glucocorticoids Modulate Dexamethasone Trial Results in Preterm Infants. Pediatrics. https://doi.org/10.1542/peds.2010-0597

Onland W, Offringa M, Cools F, et al (2011) Systemic hydrocortisone to prevent bronchopulmonary dysplasia in preterm infants (the SToP-BPD study); a multicenter randomized placebo controlled trial. BMC Pediatrics. https://doi.org/10.1186/1471-2431-11-102

Quan M (2013) Long-term effects of postnatal dexamethasone administration in prevention or treatment of chronic lung disease in preterm infants: a Meta-analysis. BMJ. https://doi.org/10.3760/CMA.J.ISSN.1671-7368.2013.08.012

Halbmeijer N, Onland W, Cools F, et al (2020) The Effect of Systemic Hydrocortisone Initiated 7 to 14 Days After Birth in Ventilated Preterm Infants on Mortality and Neurodevelopment at 2 Years’ Corrected Age: Follow-Up of a Double-Blind, Placebo-Controlled, Multicentre, Randomised Trial. Social Science Research Network. https://doi.org/10.2139/ssrn.3745187

Halbmeijer N, Onland W, Cools F, et al (2023) Effect of systemic hydrocortisone in ventilated preterm infants on parent-reported behavioural outcomes at 2 years’ corrected age: follow-up of a randomised clinical trial. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2022-324179

(2022) Nasal high‐flow therapy during neonatal endotracheal intubation. Journal of Paediatrics and Child Health. https://doi.org/10.1111/jpc.16035

Kersbergen K (2015) Longitudinal brain development in extremely preterm newborns

(2016) Postnatal steroids and febrile seizures. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2016-311455

Crotty K, Ahronovich M, Baron IS, et al (2012) Neuropsychological and behavioral effects of postnatal dexamethasone in extremely low birth weight preterm children at early school age. Journal of Perinatology. https://doi.org/10.1038/jp.2011.62

Cassiano RGM, Gaspardo CM, Linhares M (2016) PREMATURITY, NEONATAL HEALTH STATUS, AND LATER CHILD BEHAVIORAL/EMOTIONAL PROBLEMS: A SYSTEMATIC REVIEW. Infant Mental Health Journal. https://doi.org/10.1002/imhj.21563

Gentle S, Rysavy M, Li L, et al (2023) Heterogeneity of Treatment Effects of Hydrocortisone by Risk of Bronchopulmonary Dysplasia or Death Among Extremely Preterm Infants in the National Institute of Child Health and Human Development Neonatal Research Network Trial. JAMA Network Open. https://doi.org/10.1001/jamanetworkopen.2023.15315

Afifi J, Richter L, Lee S, et al (2024) 73 Predictors of neurodevelopmental impairment in extreme preterm infants with unremarkable cranial ultrasound: A Canadian population-based cohort. Paediatrics & Child Health. https://doi.org/10.1093/pch/pxae067.072

Demauro S, Kirpalani H, Ziolkowski K, et al (2024) The HYdrocortisone for Bronchopulmonary Dysplasia Respiratory and Developmental (HYBRiD) outcomes study: protocol for a longitudinal cohort study. BMC Pediatrics. https://doi.org/10.1186/s12887-024-05198-9

Marr BL, Mettelman BB, Bode MM, Gross S (2020) Reply. Jornal de Pediatria. https://doi.org/10.1016/j.jpeds.2019.12.074

Liu P, Liu S, Zhang J (2026) Identifying the risk factors of autism spectrum disorders in infants born preterm: a systematic review and meta-analysis. European Child and Adolescent Psychiatry. https://doi.org/10.1007/s00787-025-02946-9

Matthews LG, Matthews LG, Inder T, et al (2018) Longitudinal Preterm Cerebellar Volume: Perinatal and Neurodevelopmental Outcome Associations. Cerebellum. https://doi.org/10.1007/s12311-018-0946-1

Shinwell E, Gurevitz P, Portnov I (2021) Current evidence for prenatal and postnatal corticosteroids in preterm infants. Archives of Disease in Childhood. https://doi.org/10.1136/archdischild-2020-319706

Sankar MN, Chock V, Myers F, et al (2025) Patent Ductus Arteriosus, Hydrocortisone, and Outcome among Infants Born Extremely Preterm: Secondary Analysis of the Hydrocortisone Trial. Jornal de Pediatria. https://doi.org/10.1016/j.jpeds.2025.114535

Olaloko O, Mohammed R, Ojha U (2018) Evaluating the use of corticosteroids in preventing and treating bronchopulmonary dysplasia in preterm neonates. International Journal of General Medicine. https://doi.org/10.2147/IJGM.S158184

Pin T, Eldridge B, Galea M (2010) Motor trajectories from 4 to 18 months corrected age in infants born at less than 30 weeks of gestation. Early Human Development. https://doi.org/10.1016/j.earlhumdev.2010.07.008

Spénard S, Pirzada S, Jasani B, Kharrat A (2025) 92 Systemic corticosteroids in neonates with septic shock: A systematic review. Paediatrics & Child Health. https://doi.org/10.1093/pch/pxaf116.092

Meijer J, Leenen S, Vugs B, et al (2026) A longitudinal perspective on behavioral outcomes of preterm children: looking beyond composite scales. Frontiers in Developmental Psychology. https://doi.org/10.3389/fdpys.2025.1705552

He Y, Zhang Y, Gao S, et al (2020) Hydrocortisone to treat early bronchopulmonary dysplasia in very preterm infants: study protocol for a randomized controlled trial. Trials. https://doi.org/10.1186/s13063-020-04698-0

Menshykova A, Dobryanskyy D (2026) STEROIDS FOR THE PREVENTION AND TREATMENT OF BRONCHOPULMONARY DYSPLASIA IN PRETERM INFANTS: EFFECTIVENESS AND RISKS. Neonatology surgery and perinatal medicine. https://doi.org/10.24061/2413-4260.xvi.1.59.2026.29

Downloads

Published

2026-05-14

How to Cite

Deskafiani Putri, and Firman Syahbana. 2026. “Association Between Postnatal Steroid Use and Long-Term Neurodevelopmental Impairment : A Systematic Review”. The International Journal of Medical Science and Health Research 47 (2): 78-156. https://doi.org/10.70070/swdy1825.